Qlife fully secures ongoing rights issue with top guarantee commitments
Qlife Holding AB (“Qlife” or the “Company”) has secured a top guarantee syndicate, in addition to the previously announced guarantee syndicate, in the ongoing rights issue of units which was announced through a press release on 16 February 2023 (the “Rights Issue”). The top guarantee syndicate amounts to approximately SEK 16.6 million, which corresponds to approximately 28.7 percent of the Rights Issue. Consequently, the Rights Issue is secured to 100 percent through the previously announced subscription undertakings and guarantee commitments and the top guarantee syndicate.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.
In addition to the previously announced guarantee commitments, Qlife has secured a top guarantee syndicate in the ongoing Rights Issue, amounting to approximately SEK 16.6 million, corresponding to approximately 28.7 percent of the Rights Issue. Consequently, the Rights Issue is secured to 100 percent through the earlier announced subscription undertakings and guarantee commitments, and the top guarantee syndicate.
A guarantee fee will be paid to the top guarantors, based on current market conditions, of twenty (20) percent of the guaranteed and allotted amount. Twelve (12) percent of the fee will be paid in cash and eight (8) percent is to be offset against units to the same terms and conditions as for the other guarantee commitments entered into in connection with the Rights Issue. The guarantee compensation in newly issued units is to be effectuated by a directed issue of units, resolved by the board of directors based on the authorization granted by the extraordinary general meeting on 24 March 2023.
The guarantee commitments are not secured through bank guarantees, restricted funds, pledged assets or similar arrangements.
Due to the top guarantee commitments, Qlife will prepare a supplementary prospectus (the “Supplementary Prospectus”) to the EU growth prospectus that was published on 6 April 2023 (the “Prospectus”). The Supplementary Prospectus, that will be published and announced through a separate press release once approved by the Swedish Financial Supervisory Authority, will include further information regarding the parties who have entered into top guarantee commitments.
Advisers
G&W Fondkommission acts as financial advisor and Setterwalls Advokatbyrå AB acts as legal advisor to Qlife in connection with the Rights Issue. Aqurat Fondkommission AB acts as issuing agent in connection with the Rights Issue.
This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-04-2023 09:50 CET.
For more information please contact:
Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34
Qlife is a medical device company born to challenge the status quo in healthcare. We work to shift the perspective and turn today's view on healthcare into tomorrow's focus on health- empowerment. We are on a quest to empower people with more accessible ways to understand their health - so that they can move beyond reactive care towards proactive wellbeing. It's how we contribute to improving quality of life for every individual and for the greater society.
Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor.
Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.